Shares of the small-cap biotech Evofem Biosciences (NASDAQ:EVFM) rose by as much as 42.5% in pre-market trading Tuesday morning. The company's stock is taking flight in response to the Food and Drug Administration's (FDA) approval for the non-hormonal contraceptive vaginal gel Phexxi last Friday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,